Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy

RICHMOND, Calif., Oct. 17, 2017 /PRNewswire/ --Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today presentations by Company scientists at the 2017 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT). The meeting is being held in Berlin, Germany from October 17-20(th).

The following presentations are scheduled at the 2017 ESGCT meeting:

    --  Michael Holmes, Ph.D., VP, Research, will present an overview of
        Sangamo's optimized zinc finger nuclease (ZFN) architectures for
        therapeutic genome editing.Title: New zinc finger nuclease architectures
        for precision genome engineering in the development of novel genomic
        therapiesInvited Talk - Friday, October 20(th)
    --  Anthony Conway, Ph.D., Sangamo scientist, will present additional
        research data on ZFN-mediated in vivo genome editing using the Company's
        lipid nanoparticle delivery platform.Title: In vivo genome editing via
        non-viral delivery of zinc finger nucleases enables supraphysiological
        levels of therapeutic proteins and greater than 90% protein knockdown of
        multiple therapeutic gene targets via targeted integration and NHEJ,
        respectively, in wild type miceOral Presentation - Wednesday, October
    --  Marshall Huston, Ph.D., Sangamo scientist, will present an update on the
        Company's preclinical stage gene therapy program for Fabry
        disease.Title: Liver-based expression of the human alpha-galactosidase A
        gene in murine Fabry model results in continuous high, therapeutic
        levels of enzyme activity and effective substrate reductionPoster
        Presentation - Wednesday, October 18(th)

Webcasting services are not provided at this meeting.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit

View original content with multimedia:

SOURCE Sangamo Therapeutics, Inc.